Other News

Synchron Completes Patient Enrollment for COMMAND Trial of Brain Computer Interface

NEW YORK–(BUSINESS WIRE)–Synchron, the endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced completion of patient enrollment in the US-based COMMAND trial. “We look forward to announcing the results from our COMMAND study and will continue to advance development of Synchron Switch […]

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of August 31, 2023

ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of August 31, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code […]

BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy results for the ongoing Phase III pivotal trial of CardiAMP® Cell Therapy […]

Cordis Names Scott Drake Executive Chairman

MIAMI LAKES, Fla., Sept. 5, 2023 /PRNewswire/ — Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announced the appointment of Scott Drake as Executive Chairman of its Board of Directors. Drake, who joined the Cordis board in August of 2021, succeeds Duke Rohlen who served as Executive Chairman since […]

First Patient with NyokAssist™ Interventional Ventricular Assist Device: Dr. Junbo Ge’s team successfully completed the first high-risk PCI treatment supported by the new generation of interventional VAD

SUZHOU, China, Sept. 5, 2023 /PRNewswire/ — Recently, NyokAssist™ was first-in-man (FIM) use, supporting High-risk PCI completed by Dr. Junbo Ge’s team from Zhongshan Hospital in Shanghai. This successful implementation of HRPCI initially confirmed the safety and effectiveness of NyokAssist™ in assisting high-risk PCI. The patient is a 48-year-old male, who was diagnosed with […]

MedAlliance announces enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study

GENEVA, Sept. 5, 2023 /PRNewswire/ — The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR™. This is a trial initiated by physicians at the Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, which is where the first patient was enrolled. […]

FIGS and Eko Health Collaborate on the FIGS | Eko CORE 500™ Digital Stethoscope

SANTA MONICA, Calif. & EMERYVILLE, Calif.–(BUSINESS WIRE)–FIGS, Inc. (NYSE: FIGS), the direct-to-consumer healthcare apparel and lifestyle brand, and Eko Health, Inc. (“Eko”), a leading innovator in digital health technology for heart and lung disease detection, today announced the launch of the FIGS | Eko CORE 500™ Digital Stethoscope. “FIGS has built an innovative […]

Peijia Medical Announces 2023 Interim Results

HONG KONG , Sept. 1, 2023 /PRNewswire/ — Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, today announced financial results for the six months ended June 30, 2023 (“the period”). Financial Highlights During the period, the Company recorded an operating revenue of RMB224.9 […]

Bayer Expands Clinical Development Program Investigating Finerenone for Potential Treatment of Heart Failure

WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia® (finerenone) as a potential treatment for heart failure (HF) — with the initiation of three additional investigator-sponsored collaborative studies.1,2,3,4 Recruiting approximately 15,000 patients, MOONRAKER is expected to be one of the largest heart failure (HF) […]

Rapid Medical™ Gains Approval in China for the World’s Only Adjustable Thrombectomy Device

YOKNEAM, Israel & MIAMI–(BUSINESS WIRE)–Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval for its TIGERTRIEVER revascularization device. With this milestone of National Medical Product Administration (NMPA) approval, TIGERTRIEVER becomes the first device to offer patient-specific solutions for removing blood clots from the brain to advance the treatment of ischemic […]